MX353813B - Moleculas de union a vegf. - Google Patents

Moleculas de union a vegf.

Info

Publication number
MX353813B
MX353813B MX2013002379A MX2013002379A MX353813B MX 353813 B MX353813 B MX 353813B MX 2013002379 A MX2013002379 A MX 2013002379A MX 2013002379 A MX2013002379 A MX 2013002379A MX 353813 B MX353813 B MX 353813B
Authority
MX
Mexico
Prior art keywords
vegf
binding molecules
binding
anddomain
vhhs
Prior art date
Application number
MX2013002379A
Other languages
English (en)
Other versions
MX2013002379A (es
Inventor
Merchiers Pascal
Borges Eric
Gschwind Andreas
Boucneau Joachim
De Tavernier Evelyn
Kolkman Joost
Original Assignee
Boehringer Ingelheim Int Gmbh Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43530923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX353813(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int Gmbh Star filed Critical Boehringer Ingelheim Int Gmbh Star
Publication of MX2013002379A publication Critical patent/MX2013002379A/es
Publication of MX353813B publication Critical patent/MX353813B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a moléculas de unión a VEGF, preferiblemente dominios variables individuales de inmunoglobulina de unión a VEGF tales como los VHHs y los anticuerpos de dominio, composiciones farmacéuticas que contienen los mismos y su uso en el tratamiento de enfermedades que están asociadas con los efectos sobre la angiogénesis mediados por el VEGF. Ácidos nucleicos que codifican moléculas de unión a VEGF, células hospedantes y métodos para la preparación de los mismos.
MX2013002379A 2010-09-03 2011-09-02 Moleculas de union a vegf. MX353813B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175318 2010-09-03
PCT/EP2011/065199 WO2012028716A1 (en) 2010-09-03 2011-09-02 Vegf-binding molecules

Publications (2)

Publication Number Publication Date
MX2013002379A MX2013002379A (es) 2013-05-09
MX353813B true MX353813B (es) 2018-01-31

Family

ID=43530923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002379A MX353813B (es) 2010-09-03 2011-09-02 Moleculas de union a vegf.

Country Status (16)

Country Link
US (6) US20120225081A1 (es)
EP (2) EP2611830A1 (es)
JP (1) JP5979504B2 (es)
KR (1) KR101844875B1 (es)
CN (1) CN103209995B (es)
AR (1) AR082892A1 (es)
AU (1) AU2011298281B2 (es)
BR (1) BR112013005151A2 (es)
CA (1) CA2808696C (es)
CL (1) CL2013000596A1 (es)
EA (1) EA029277B1 (es)
IL (1) IL224800B (es)
MX (1) MX353813B (es)
NZ (1) NZ607394A (es)
UY (1) UY33588A (es)
WO (1) WO2012028716A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2014031856A1 (en) * 2012-08-23 2014-02-27 Onconthyreon Inc. Combination therapy using pi3 kinase and braf inhibitors
KR101541478B1 (ko) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016109943A1 (zh) * 2015-01-06 2016-07-14 珠海亿胜生物制药有限公司 抗vegf抗体
KR102501921B1 (ko) * 2016-03-08 2023-02-21 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
US11254738B2 (en) * 2016-09-07 2022-02-22 The Governing Council Of The University Of Toronto Banting Institute Synthetic antibodies against VEGF and their uses
WO2018175319A1 (en) * 2017-03-20 2018-09-27 Allergan, Inc. Heavy chain only antibodies to vegf
PE20212205A1 (es) 2017-09-08 2021-11-18 Maverick Therapeutics Inc Proteinas de union condicionalmente activadas restringidas
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
WO2022031964A2 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr1 binding molecules and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
AU2022223337A1 (en) * 2021-02-19 2023-09-21 Dotbio Pte. Ltd. Vegfa-binding molecules
JP2024529119A (ja) * 2021-08-13 2024-08-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途
CN113896805B (zh) * 2021-12-13 2022-02-25 上海惠盾因泰生物科技有限公司 一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用
CN116284405B (zh) * 2023-03-15 2024-03-19 中国科学技术大学 靶向cd150蛋白的纳米抗体及其应用
CN118085081B (zh) * 2024-04-19 2024-06-21 云南大学 一种特异性结合vegf的纳米抗体及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
NZ527591A (en) 2001-01-17 2006-04-28 Trubion Pharmaceuticals Inc Binding domain-immunoglobulin fusion proteins
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
US20050043220A1 (en) * 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
EP1639011B1 (en) 2003-06-30 2008-11-12 Domantis Limited Pegylated single domain antibodies (dAb)
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
CL2007001624A1 (es) 2006-06-06 2008-01-18 Genentech Inc Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2009004027A (es) * 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
MX2010004327A (es) * 2007-10-22 2010-05-13 Schering Corp Anticuerpos anti-vegf completamente humanos y metodos de uso.
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109635A2 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy

Also Published As

Publication number Publication date
EA201300311A1 (ru) 2013-08-30
IL224800B (en) 2020-03-31
US20120225081A1 (en) 2012-09-06
US20220363744A1 (en) 2022-11-17
CL2013000596A1 (es) 2014-02-14
EP2727939A2 (en) 2014-05-07
JP2013541939A (ja) 2013-11-21
MX2013002379A (es) 2013-05-09
CN103209995B (zh) 2015-11-25
UY33588A (es) 2012-03-30
EP2727939A3 (en) 2014-05-21
AU2011298281A1 (en) 2013-03-14
US20180201671A1 (en) 2018-07-19
WO2012028716A1 (en) 2012-03-08
EP2611830A1 (en) 2013-07-10
KR20130101045A (ko) 2013-09-12
US20240141030A1 (en) 2024-05-02
KR101844875B1 (ko) 2018-04-03
US20160200806A1 (en) 2016-07-14
US20200308267A1 (en) 2020-10-01
AR082892A1 (es) 2013-01-16
AU2011298281B2 (en) 2015-02-05
EA029277B1 (ru) 2018-03-30
JP5979504B2 (ja) 2016-08-24
CA2808696C (en) 2016-12-20
CN103209995A (zh) 2013-07-17
CA2808696A1 (en) 2012-03-08
BR112013005151A2 (pt) 2020-08-04
NZ607394A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2013002379A (es) Moleculas de union a vegf.
PH12014502179A1 (en) Ang2-binding molecules
TN2012000144A1 (en) Dll4-binding molecules
TN2012000145A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
PH12018500640A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
WO2014004549A3 (en) Anti-mesothelin binding proteins
NZ700856A (en) St2 antigen binding proteins
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
TN2014000360A1 (en) Cx3cr1-binding polypeptides
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
WO2012135671A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration